Prevencio Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $8.38M

  • Investors
  • 1

Prevencio General Information

Description

Developer of multi-proteomic biomarkers designed to transform blood tests for cardiovascular disease. The company's biomarkers employ artificial intelligence to interrogate well-characterized clinical data sets to produce novel, multi-protein, algorithmically-scored tests, enabling clinicians to assess pre-drug or post-drug effects on a composite of heart attack, stroke, and cardiac death.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Corporate Office
  • 6424 Lake Washington Blvd North East
  • Suite 13
  • Kirkland, WA 98033
  • United States
+1 (425) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prevencio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B1) 16-Mar-2022 $8.38M 000.00 000.00 Completed Generating Revenue
3. Accelerator/Incubator 01-Oct-2019 00.00 Completed Clinical Trials - General
2. Later Stage VC (Series B) 30-Jun-2016 $4.8M $6.8M 000.00 Completed Clinical Trials - General
1. Later Stage VC (Series A) 30-Dec-2013 $2M $2M 0000 Completed Clinical Trials - General
To view Prevencio’s complete valuation and funding history, request access »

Prevencio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-0 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B1 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B 5,562,744 $0.000100 8% $1 $1 1x $1 21.76%
Series A 3,578,826 $0.000100 8% $0.9 $0.9 1x $0.9 14%
To view Prevencio’s complete cap table history, request access »

Prevencio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of multi-proteomic biomarkers designed to transform blood tests for cardiovascular disease. The company's biom
Biotechnology
Kirkland, WA
9 As of 2022
000.00
00.00 0000-00-00
00000000000 000.00

00000

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolo
0000000000000
Aliso Viejo, CA
000 As of 0000
00 0000-00-00
000000&0

000000

e dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000000000000
Austin, TX
0000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prevencio Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ambry Genetics Corporate Backed or Acquired Aliso Viejo, CA 000 000000&0
Natera Formerly VC-backed Austin, TX 0000 00000 00000000 00000
Positive Biosciences Corporation Mumbai, India 00
One BioMed Venture Capital-Backed Singapore, Singapore 00 000.00 0000000000 0 000.00
23Mofang Venture Capital-Backed Chengdu, China 000.00 00000000000 000.00
You’re viewing 5 of 9 competitors. Get the full list »

Prevencio Patents

Prevencio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220178946-A1 Prognostic and diagnostic methods for risk of acute kidney injury Pending 02-Nov-2018 00000000000
EP-3704491-A1 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending 02-Nov-2017 00000000000
US-20220229071-A1 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending 02-Nov-2017 00000000000 0
CA-3081752-A1 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending 02-Nov-2017 00000000000
EP-3704491-A4 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending 02-Nov-2017 G01N33/6893
To view Prevencio’s complete patent history, request access »

Prevencio Executive Team (13)

Name Title Board Seat Contact Info
Rhonda Rhyne Chief Executive Officer, Chief Translational Officer, President & Board Member
Michele McCarthy Chief Financial Officer & Board Member
Celine Peters Chief Operating Officer
Grady Barnes Ph.D Chief Scientific Officer
William LaFramboise Ph.D Co-Founder & Consultant
You’re viewing 5 of 13 executive team members. Get the full list »

Prevencio Board Members (7)

Name Representing Role Since
Arlen Prentice Self Board Observer 000 0000
John Cramer III Self Board Member 000 0000
Joseph Strecker Self Board Observer 000 0000
Michele McCarthy Prevencio Chief Financial Officer & Board Member 000 0000
Rhonda Rhyne Prevencio Chief Executive Officer, Chief Translational Officer, President & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Prevencio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prevencio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
G4A Accelerator/Incubator Minority 000 0000 000000 0
To view Prevencio’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »